130 related articles for article (PubMed ID: 10617694)
41. Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice.
Chen C; Pollack GM
J Pharmacol Exp Ther; 1998 Nov; 287(2):545-52. PubMed ID: 9808679
[TBL] [Abstract][Full Text] [Related]
42. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted.
Smit JW; Schinkel AH; Weert B; Meijer DK
Br J Pharmacol; 1998 May; 124(2):416-24. PubMed ID: 9641561
[TBL] [Abstract][Full Text] [Related]
43. Lipopolysaccharide treatment downregulates the expression of the pregnane X receptor, cyp3a11 and mdr1a genes in mouse placenta.
Chen YH; Wang JP; Wang H; Sun MF; Wei LZ; Wei W; Xu DX
Toxicology; 2005 Aug; 211(3):242-52. PubMed ID: 15869837
[TBL] [Abstract][Full Text] [Related]
44. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers.
Salphati L; Benet LZ
Biochem Pharmacol; 1998 Feb; 55(4):387-95. PubMed ID: 9514072
[TBL] [Abstract][Full Text] [Related]
45. Multidrug resistance gene deficient (mdr1a-/-) mice have an altered caecal microbiota that precedes the onset of intestinal inflammation.
Nones K; Knoch B; Dommels YE; Paturi G; Butts C; McNabb WC; Roy NC
J Appl Microbiol; 2009 Aug; 107(2):557-66. PubMed ID: 19302324
[TBL] [Abstract][Full Text] [Related]
46. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein.
Kwei GY; Alvaro RF; Chen Q; Jenkins HJ; Hop CE; Keohane CA; Ly VT; Strauss JR; Wang RW; Wang Z; Pippert TR; Umbenhauer DR
Drug Metab Dispos; 1999 May; 27(5):581-7. PubMed ID: 10220486
[TBL] [Abstract][Full Text] [Related]
47. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.
Smit JW; Huisman MT; van Tellingen O; Wiltshire HR; Schinkel AH
J Clin Invest; 1999 Nov; 104(10):1441-7. PubMed ID: 10562306
[TBL] [Abstract][Full Text] [Related]
48. Effects of disease on expression and regulation of CYPs.
Farrell G
Mol Aspects Med; 1999; 20(1-2):55-70, 137. PubMed ID: 10575652
[No Abstract] [Full Text] [Related]
49. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.
van Asperen J; van Tellingen O; Tijssen F; Schinkel AH; Beijnen JH
Br J Cancer; 1999 Jan; 79(1):108-13. PubMed ID: 10408701
[TBL] [Abstract][Full Text] [Related]
50. Effects of intracellular glutathione on sensitivity of Escherichia coli to mercury and arsenite.
Latinwo LM; Donald C; Ikediobi C; Silver S
Biochem Biophys Res Commun; 1998 Jan; 242(1):67-70. PubMed ID: 9439611
[TBL] [Abstract][Full Text] [Related]
51. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAS in small intestine.
Takara K; Ohnishi N; Horibe S; Yokoyama T
Drug Metab Dispos; 2003 Oct; 31(10):1235-9. PubMed ID: 12975332
[TBL] [Abstract][Full Text] [Related]
52. Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a-/- mice.
Resta-Lenert S; Smitham J; Barrett KE
Am J Physiol Gastrointest Liver Physiol; 2005 Jul; 289(1):G153-62. PubMed ID: 15774938
[TBL] [Abstract][Full Text] [Related]
53. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
Schinkel AH; Wagenaar E; van Deemter L; Mol CA; Borst P
J Clin Invest; 1995 Oct; 96(4):1698-705. PubMed ID: 7560060
[TBL] [Abstract][Full Text] [Related]
54. Tissue distribution and chemical induction of multiple drug resistance genes in rats.
Brady JM; Cherrington NJ; Hartley DP; Buist SC; Li N; Klaassen CD
Drug Metab Dispos; 2002 Jul; 30(7):838-44. PubMed ID: 12065443
[TBL] [Abstract][Full Text] [Related]
55. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.
Schinkel AH; Mayer U; Wagenaar E; Mol CA; van Deemter L; Smit JJ; van der Valk MA; Voordouw AC; Spits H; van Tellingen O; Zijlmans JM; Fibbe WE; Borst P
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):4028-33. PubMed ID: 9108099
[TBL] [Abstract][Full Text] [Related]
56. Modification of the metabolism and toxicity of styrene and styrene oxide in hepatic cytochrome P450 reductase deficient mice and CYP2F2 deficient mice.
Carlson GP
Toxicology; 2012 Apr; 294(2-3):104-8. PubMed ID: 22386858
[TBL] [Abstract][Full Text] [Related]
57. Using real-time quantitative TaqMan RT-PCR to evaluate the role of dexamethasone in gene regulation of rat P-glycoproteins mdr1a/1b and cytochrome P450 3A1/2.
Mei Q; Richards K; Strong-Basalyga K; Fauty SE; Taylor A; Yamazaki M; Prueksaritanont T; Lin JH; Hochman J
J Pharm Sci; 2004 Oct; 93(10):2488-96. PubMed ID: 15349958
[TBL] [Abstract][Full Text] [Related]
58. Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs.
Smit JW; Weert B; Schinkel AH; Meijer DK
J Pharmacol Exp Ther; 1998 Jul; 286(1):321-7. PubMed ID: 9655875
[TBL] [Abstract][Full Text] [Related]
59. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats.
Kalitsky-Szirtes J; Shayeganpour A; Brocks DR; Piquette-Miller M
Drug Metab Dispos; 2004 Jan; 32(1):20-7. PubMed ID: 14709616
[TBL] [Abstract][Full Text] [Related]
60. Validation of a P-Glycoprotein (P-gp) Humanized Mouse Model by Integrating Selective Absolute Quantification of Human MDR1, Mouse Mdr1a and Mdr1b Protein Expressions with In Vivo Functional Analysis for Blood-Brain Barrier Transport.
Sadiq MW; Uchida Y; Hoshi Y; Tachikawa M; Terasaki T; Hammarlund-Udenaes M
PLoS One; 2015; 10(5):e0118638. PubMed ID: 25932627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
